MX2009005219A - Inhibidores macrociclicos del virus de hepatitis c. - Google Patents

Inhibidores macrociclicos del virus de hepatitis c.

Info

Publication number
MX2009005219A
MX2009005219A MX2009005219A MX2009005219A MX2009005219A MX 2009005219 A MX2009005219 A MX 2009005219A MX 2009005219 A MX2009005219 A MX 2009005219A MX 2009005219 A MX2009005219 A MX 2009005219A MX 2009005219 A MX2009005219 A MX 2009005219A
Authority
MX
Mexico
Prior art keywords
6alkyl
hydrogen
optionally
6alkoxy
subst ituted
Prior art date
Application number
MX2009005219A
Other languages
English (en)
Inventor
Abdellah Tahri
Vreken Wim Van De
Kock Herman Augustinus De
Pierre Jean-Marie Bernard Raboisson
Sandrine Marie Helene Vendeville
Lili Hu
Gowan David Craig Mc
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37894415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009005219(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of MX2009005219A publication Critical patent/MX2009005219A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Inhibidores de la replicación de VHC de la fórmula (I) (ver fórmula (I)) y las sales y estereoisómeros de los mismos, donde cada línea de guiones (representada por -----) representa un enlace doble opcional; X es N, CH y donde X porta un enlace doble, éste es C; R1 es -OR7, -NH-SO2R8; R2 es hidrógeno, y donde X es C o CH, R2 también puede ser alquilo C1-6; R3 es hidrógeno, alquilo C1-6, alcoxi C1-6 alquilo C1-6, cicloalquilo C3-7; n es 3, 4, 5, o 6; R4 es alquilo C1-6 o cicloalquilo C3-7; R5 es hidrógeno, halo, alquiloC1-6, hidroxi, alcoxi C1-6, polihaloalquilo C1-6; R6 es hidrógeno, alcoxi C1-6, mono- o dialquilamino C1-6; o R5 y R6 pueden formar un anillo insaturado o parcialmente insaturado de 5 o 6 miembros, que comprenden opcionalmente uno o dos seleccionados de O, N y S; R7 es hidrógeno; cicloalquilo C3-7 opcionalmente sustituido con alquilo C1-6; o alquilo C1-6 opcionalmente sustituido con cicloalquilo C3-7; R8 es cicloaqluilo C3-7 opcionalmente sustituido con alquilo C1-6; alquilo C1-6 opcionalmente sustituido con cicloalquilo C3-7; o -NR8aR8b; R8a y R8b son alquilo C1-6, o ambos pueden formar un anillo heterocíclico saturado de 5 o 6 miembros; composiciones farmacéuticas que contienen los compuestos (I) y procesos para preparar dichos compuestos (I).
MX2009005219A 2006-11-17 2007-11-16 Inhibidores macrociclicos del virus de hepatitis c. MX2009005219A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06124359 2006-11-17
PCT/EP2007/062436 WO2008059046A1 (en) 2006-11-17 2007-11-16 Macrocyclic inhibitors of hepatitis c virus

Publications (1)

Publication Number Publication Date
MX2009005219A true MX2009005219A (es) 2009-05-27

Family

ID=37894415

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005219A MX2009005219A (es) 2006-11-17 2007-11-16 Inhibidores macrociclicos del virus de hepatitis c.

Country Status (17)

Country Link
US (2) US8637663B2 (es)
EP (1) EP2097402B1 (es)
JP (2) JP2010510192A (es)
KR (1) KR20090079881A (es)
CN (1) CN101535294B (es)
AR (1) AR064258A1 (es)
AU (1) AU2007321182B2 (es)
BR (1) BRPI0718798A2 (es)
CA (1) CA2661338C (es)
CL (1) CL2007003299A1 (es)
DK (1) DK2097402T3 (es)
EA (1) EA200970493A1 (es)
ES (1) ES2470568T3 (es)
HK (1) HK1136824A1 (es)
MX (1) MX2009005219A (es)
TW (1) TWI406660B (es)
WO (1) WO2008059046A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
MY139988A (en) * 2005-07-29 2009-11-30 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
EA200970493A1 (ru) * 2006-11-17 2009-10-30 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с
US20090155209A1 (en) * 2007-05-03 2009-06-18 Blatt Lawrence M Novel macrocyclic inhibitors of hepatitis c virus replication
EP2185524A1 (en) * 2007-05-10 2010-05-19 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
AP2010005416A0 (en) * 2008-04-15 2010-10-31 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication.
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
CN102741270B (zh) * 2009-09-28 2015-07-22 英特穆恩公司 C型肝炎病毒复制的环肽抑制剂
JP2013511562A (ja) * 2009-11-24 2013-04-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎阻害化合物
CN102140100B (zh) 2010-01-27 2014-06-11 爱博新药研发(上海)有限公司 高效抑制丙型肝炎病毒的多环化合物及其制备方法和用途
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
WO2012109398A1 (en) * 2011-02-10 2012-08-16 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012171332A1 (zh) 2011-06-16 2012-12-20 爱博新药研发(上海)有限公司 抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN104557954A (zh) * 2013-10-16 2015-04-29 上海唐润医药科技有限公司 抗hcv的大环化合物
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
JP7208074B2 (ja) 2019-03-19 2023-01-18 Ntn株式会社 出力電圧検出回路

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087876A (en) * 1990-07-16 1992-02-11 Semitest, Inc. Apparatus and method for making surface photovoltage measurements of a semiconductor
DK0727419T3 (da) 1992-12-29 2002-06-10 Abbott Lab Mellemprodukter til fremstilling af forbindelser, som inhiberer retroviral protease
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
NZ332405A (en) 1996-04-23 2000-06-23 Vertex Pharma oxazolyl, thiazolyl or phenyl urea derivatives as inhibitors of inosine monophosphate dehydrogenase enzyme
ES2201452T3 (es) 1997-03-14 2004-03-16 Vertex Pharmaceuticals Incorporated Inhibidores de la enzima impdh.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
TR200103428T2 (tr) 1999-03-19 2002-04-22 Vertex Pharmaceuticals Incorporated IMPDH enzim inhibitörleri.
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
PL373399A1 (en) 2002-04-11 2005-08-22 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
WO2005073195A2 (en) * 2004-01-30 2005-08-11 Medivir Ab Hcv ns-3 serine protease inhibitors
UY29016A1 (es) * 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
MY139988A (en) * 2005-07-29 2009-11-30 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis c virus
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20070210A1 (es) * 2005-07-29 2007-04-16 Tibotec Pharm Ltd Compuestos macrociclicos como inhibidores del virus de hepatitis c
TW200745061A (en) * 2005-07-29 2007-12-16 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis C virus
PE20070343A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c
CN101273038A (zh) * 2005-07-29 2008-09-24 美迪维尔公司 丙型肝炎病毒的大环化合物抑制剂
EA200970493A1 (ru) * 2006-11-17 2009-10-30 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с

Also Published As

Publication number Publication date
CL2007003299A1 (es) 2008-08-22
CN101535294A (zh) 2009-09-16
HK1136824A1 (en) 2010-07-09
EP2097402A1 (en) 2009-09-09
ES2470568T3 (es) 2014-06-24
CA2661338C (en) 2015-05-12
CN101535294B (zh) 2014-09-24
AR064258A1 (es) 2009-03-25
JP2010510192A (ja) 2010-04-02
TWI406660B (zh) 2013-09-01
WO2008059046A1 (en) 2008-05-22
US20140113929A1 (en) 2014-04-24
BRPI0718798A2 (pt) 2013-12-03
EP2097402B1 (en) 2014-04-09
US20100022578A1 (en) 2010-01-28
EA200970493A1 (ru) 2009-10-30
JP6153495B2 (ja) 2017-06-28
AU2007321182B2 (en) 2013-11-14
KR20090079881A (ko) 2009-07-22
TW200838529A (en) 2008-10-01
US9365582B2 (en) 2016-06-14
DK2097402T3 (da) 2014-06-30
JP2014221756A (ja) 2014-11-27
AU2007321182A1 (en) 2008-05-22
US8637663B2 (en) 2014-01-28
CA2661338A1 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
MX2009005219A (es) Inhibidores macrociclicos del virus de hepatitis c.
SG163617A1 (en) Macrocyclic inhibitors of hepatitis c virus
TW200745118A (en) Macrocylic inhibitors of hepatitis C virus
TW200740775A (en) Macrocylic inhibitors of hepatitis C virus
SG163610A1 (en) Macrocyclic inhibitors of hepatitis c virus
TW200800949A (en) Macrocylic inhibitors of hepatitis C virus
TW200745061A (en) Macrocylic inhibitors of hepatitis C virus
TW200642683A (en) Heterocyclic compound
NO20092279L (no) Makrocyklisk factor VIIa inhibitorer anvendbare som antikoagulanter
CO6270320A2 (es) Derivados de piperidina utiles como antagonistas del receptor orexina
NZ536734A (en) Spiroindolinepiperidine derivatives
TW200800945A (en) Macrocylic inhibitors of hepatitis c virus
CO5650252A2 (es) Inhibidores de quinesina mitotica
TW200716576A (en) Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
MY161631A (en) Herbicidal pyrimidone derivatives
NO20082629L (no) Macrocyklisk factor VIIa-inhibitorer anvendbare som antikoagulanter
UA99466C2 (en) Crystalline pyridazine compound
TW200716571A (en) Heterocyclic reverse transcriptase inhibitors
PE20090548A1 (es) Compuestos aza-biciclohexano como inhibidores de trombina
MY136824A (en) Substituted benzoxazinones and uses thereof
MXPA04000494A (es) Antagonistas del factor liberador de corticotropina hetero-biciclico.
NO20074346L (no) Nye heterocykliske oksimforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
WO2007144769A8 (en) Aryl- and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their application in therapeutics
TW200738681A (en) Isoquinoline and benzo[h]isoquinoline derivatives, their preparation and their use in therapeutics
MX2009005782A (es) Derivados de pirano, procedimiento de preparacion y uso de los mismos en perfumeria y saborizantes.

Legal Events

Date Code Title Description
FG Grant or registration